Overview

Study to Evaluate MET642 in Patients With NASH

Status:
Active, not recruiting
Trial end date:
2022-02-14
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled study to evaluate MET642 in NASH patients.
Phase:
Phase 2
Details
Lead Sponsor:
Metacrine, Inc.